Successful, we will reply to you quickly.


Please select the quantity.


Your message is being sent, please wait.




Send mail failed, please send again!


Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway



(KW-2307 base)


Vinorelbine Chemical Structure

Vinorelbine(KW-2307 base) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.


CAS No.: 71486-22-1 Backordered

Size Price Stock Quantity
10 mg $60 Backordered
50 mg $180 Backordered

Vinorelbine ditartrate

CAS No.: 125317-39-7 In-stock

Bulk Inquiry

Inquiry Information
Product name: Vinorelbine
Cat. No.: HY-12053

Vinorelbine Data Sheet

  • Network Version


Related Compound Libraries

Biological Activity of Vinorelbine

Vinorelbine(KW-2307 base) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
IC50 value:
Target: Anti-mitotic
Vinorelbine (Navelbine) is the first 5′NOR semi-synthetic vinca alkaloid and exerts its activity through the MAPK (p38) pathway with median IC90 and IC50 of 15.5 and 2.3 μM. Vinorelbine induces concentration- and time-dependent increases in the protein levels of both p53 and p21 in hormone-dependent (AD) LNCaP cells, and can restore p21 expression in androgen-independent (AI) prostate cancer cells through both p53-dependent and-independent pathways.

Chemical Information

M.Wt 778.93 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₄₅H₅₄N₄O₈
CAS No 71486-22-1
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.2838 mL 6.4191 mL 12.8381 mL
5 mM 0.2568 mL 1.2838 mL 2.5676 mL
10 mM 0.1284 mL 0.6419 mL 1.2838 mL

Clinical Information of Vinorelbine

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Vinorelbine Chinese Academy of Medical Sciences Breast tumor 31-JUL-10 31-AUG-15 Phase 3 13-SEP-13
Boehringer Ingelheim Corp Metastatic breast cancer 30-JUN-10 31-MAY-16 Phase 3 15-NOV-13
Shanghai Jiao Tong University Non-small-cell lung cancer 31-JUL-07 31-OCT-09 Phase 3 24-OCT-13
Eisai Inc Metastatic non small cell lung cancer 30-SEP-11 Phase 3 14-NOV-13
MolMed SpA Mesothelioma 31-MAR-10 31-DEC-13 Phase 3 31-JAN-13

References on Vinorelbine

Inhibitor Kit

Related Microtubule/Tubulin Products

  • 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • 10-Oxo Docetaxel

    10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

  • 2-Methoxyestradiol

    2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.

  • 4'-Demethylepipodophyllotoxin

    4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.

  • 7-Epi-10-oxo-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

  • 7-Epi-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

  • 7-xylosyltaxol

    7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.

  • ABT-751

    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.

  • Auristatin E

    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

  • Auristatin F

    Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.